Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

789.32 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments. 
Via Benzinga
Topics ETFs
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits 
Via Benzinga
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
The weight loss drug market is growing rapidly. 
Via The Motley Fool
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. 
Via InvestorPlace
Topics Economy
Exposures Economy
Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile
The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10. This review assesses the drug's benefit-risk profile based on significant efficacy... 
Via Benzinga
Exposures Product Safety
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $700 Today
Via Benzinga
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Is Viking Therapeutics Stock a Buy on the Dip?
Short-term thinking is creating an intriguing opportunity for investors. 
Via The Motley Fool
Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half
Although going with the crowd comes with a certain comfort level, daring investors may want to consider these less-discussed momentum stocks. 
Via InvestorPlace
Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition
Investors who want to put some sizzle in their portfolios should consider investing in these growth names that offer big returns. 
Via InvestorPlace
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Via Benzinga
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new avenues for long-term treatment. 
Via Benzinga
Google Parent Alphabet Appoints Eli Lilly's Finance Chief Ashkenazi As CFO
Anat Ashkenazi resigns as CFO of Eli Lilly to join Google as CFO and SVP. She will remain at Lilly until July 2024 while her successor is sought. 
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
Via Investor's Business Daily
Alphabet Picks Eli Lilly Executive Anat Ashkenazi As New CFO
Google stock rose after Alphabet announced that its new CFO will be Anat Ashkenazi, currently an executive at drug maker Eli Lilly. 
Via Investor's Business Daily
AMZN Buy Alert: Why Amazon Stock Is a Bargain Hiding in Plain Sight
The valuation of Amazon stock is quite low while multiple, large investors bought significant amounts of the shares in Q1. 
Via InvestorPlace
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target 
Via Benzinga
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other neurodegenerative diseases. QurAlis will receive $45 million upfront, with... 
Via Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
The fight for dominance in the weight loss market is just getting started. 
Via The Motley Fool
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
4 Stocks Making New Highs Despite Market Weakness
While the market faced challenges on Friday, Birkenstock, NetApp, Eli Lilly, and Aflac showed notable strength by achieving new 52-week highs. 
Via MarketBeat
The Week Ahead: What's Next
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
These two drugmakers have a lot more in common than their market-beating potential. 
Via The Motley Fool
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs. 
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.